At the J.P. Morgan Healthcare Conference, Hippocratic AI announced a strategic expansion into the life sciences sector through the acquisition of Grove AI, a company focused on agentic AI for clinical trial operations. Grove AI’s technology supports patient and participant engagement, recruitment, and operational workflows in clinical research, extending Hippocratic AI’s capabilities beyond patient-facing care delivery into biopharma and medtech environments.
Alongside the acquisition, Hippocratic AI formed a dedicated life sciences division, appointed a president to lead the business, and established a life sciences executive advisory council to guide product strategy and deployment. This move positions the company to apply its safety-focused, multi-agent AI approach to regulated research and development settings, signaling an effort to address operational inefficiencies in clinical trials while maintaining its emphasis on specialized, domain-specific AI systems.